Key Takeaways
- • Cleveland Clinic and Khosla Ventures established a strategic collaboration enabling portfolio companies to access clinical validation environments across all development stages, from early research through commercial deployment at one of the world's leading health systems.
- • Khosla Ventures portfolio companies gain a direct pipeline to Cleveland Clinic providers for technology testing and refinement, accelerating time-to-market for startups in artificial intelligence, digital health, and next-generation therapeutics.
- • Cleveland Clinic secures direct access to emerging technologies and Khosla Ventures' entrepreneurial network, positioning the health system to evaluate innovations at earlier stages and integrate proven solutions into clinical practice.
- • Khosla Ventures will lead technical development and recruiting under the partnership structure, while Cleveland Clinic provides the clinical environment and biomedical research expertise required for validation and scaling.
- • The collaboration addresses healthcare's most pressing challenges by connecting Silicon Valley venture capital with institutional clinical expertise, leveraging AI as a core focus area given its transformative potential in medical care delivery.
Summary
Cleveland Clinic and Khosla Ventures announced a strategic collaboration on October 15, 2025, creating a formal partnership between a major U.S. health system and one of Silicon Valley's most active healthcare-focused venture investors. The collaboration establishes a structured pathway for Khosla Ventures' portfolio companies to validate and commercialize emerging technologies within Cleveland Clinic's clinical environment.
The partnership gives Khosla Ventures-backed startups direct access to Cleveland Clinic providers across all stages of development—from clinical validation through commercial adoption. This access enables companies to demonstrate technology value directly with practicing clinicians, addressing a critical bottleneck for healthcare startups seeking real-world evidence and regulatory pathways. For Cleveland Clinic, the arrangement creates an inbound innovation channel, granting the health system early exposure to emerging solutions in artificial intelligence, digital health, and next-generation therapeutics without requiring internal R&D investment.
Hal Paz, MD, operating partner at Khosla Ventures and former CEO of large-scale health systems, framed AI as the central focus of the collaboration, calling it "the most transformative technology of our lifetime" with significant implications for healthcare delivery and outcomes. Geoff Vince, PhD, Chief of Cleveland Clinic Innovations, characterized the partnership as synergistic, combining Cleveland Clinic's biomedical research capabilities and clinical expertise with Khosla Ventures' venture capital resources and entrepreneurial network.
Under the collaboration structure, Khosla Ventures assumes responsibility for technical development and recruiting, while Cleveland Clinic provides the clinical testing environment, research infrastructure, and provider access necessary for rigorous validation. This division of labor reflects institutional comparative advantage: the venture capital firm's ability to identify and nurture early-stage founders, paired with the health system's regulatory relationships, patient populations, and clinical credibility. The arrangement aims to accelerate the journey from concept to scalable healthcare solutions, addressing persistent challenges in healthcare delivery, efficiency, and outcomes.
The partnership gives Khosla Ventures-backed startups direct access to Cleveland Clinic providers across all stages of development—from clinical validation through commercial adoption. This access enables companies to demonstrate technology value directly with practicing clinicians, addressing a critical bottleneck for healthcare startups seeking real-world evidence and regulatory pathways. For Cleveland Clinic, the arrangement creates an inbound innovation channel, granting the health system early exposure to emerging solutions in artificial intelligence, digital health, and next-generation therapeutics without requiring internal R&D investment.
Hal Paz, MD, operating partner at Khosla Ventures and former CEO of large-scale health systems, framed AI as the central focus of the collaboration, calling it "the most transformative technology of our lifetime" with significant implications for healthcare delivery and outcomes. Geoff Vince, PhD, Chief of Cleveland Clinic Innovations, characterized the partnership as synergistic, combining Cleveland Clinic's biomedical research capabilities and clinical expertise with Khosla Ventures' venture capital resources and entrepreneurial network.
Under the collaboration structure, Khosla Ventures assumes responsibility for technical development and recruiting, while Cleveland Clinic provides the clinical testing environment, research infrastructure, and provider access necessary for rigorous validation. This division of labor reflects institutional comparative advantage: the venture capital firm's ability to identify and nurture early-stage founders, paired with the health system's regulatory relationships, patient populations, and clinical credibility. The arrangement aims to accelerate the journey from concept to scalable healthcare solutions, addressing persistent challenges in healthcare delivery, efficiency, and outcomes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.